S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

$497.79
-5.31 (-1.06%)
(As of 04/12/2024 ET)
Today's Range
$492.99
$501.44
50-Day Range
$497.79
$576.87
52-Week Range
$372.50
$583.39
Volume
513,717 shs
Average Volume
371,766 shs
Market Capitalization
$41.34 billion
P/E Ratio
49.43
Dividend Yield
N/A
Price Target
$591.50

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
18.8% Upside
$591.50 Price Target
Short Interest
Healthy
2.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
1.04mentions of IDEXX Laboratories in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$24.87 M Sold Last Quarter
Proj. Earnings Growth
14.53%
From $11.15 to $12.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.71 out of 5 stars

Medical Sector

62nd out of 923 stocks

Diagnostic Substances Industry

2nd out of 12 stocks

IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
IDXX Oct 2024 780.000 call
IDXX Apr 2024 280.000 put
IDXX Jun 2024 640.000 call
IDXX Feb 2024 550.000 call
IDEXX Laboratories Inc Insider Sells Shares
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
4/13/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
11,000
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$591.50
High Stock Price Target
$655.00
Low Stock Price Target
$460.00
Potential Upside/Downside
+18.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$845.04 million
Pretax Margin
28.99%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$11.44 per share
Book Value
$17.88 per share

Miscellaneous

Free Float
81,302,000
Market Cap
$41.34 billion
Optionable
Optionable
Beta
1.26

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Strong financial performance: IDEXX Laboratories reported earnings per share that exceeded analysts' expectations, indicating a healthy financial position.
  • Diverse product portfolio: The company offers a wide range of diagnostic products for various markets, including veterinary, livestock, and water testing, which can contribute to revenue stability.
  • Market leadership: IDEXX Laboratories is a key player in the diagnostic substances industry, showcasing its expertise and market dominance.
  • Steady stock performance: Despite market fluctuations, IDEXX Laboratories stock has shown stability and resilience, appealing to risk-averse investors.
  • Innovative solutions: The company continues to introduce cutting-edge diagnostic and health-monitoring products, staying ahead of competitors and meeting evolving market demands.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Market volatility: The stock market can be unpredictable, impacting IDEXX Laboratories' stock price and potentially leading to investment risks.
  • Competition: The company operates in a competitive industry, facing challenges from other players that could affect market share and profitability.
  • Regulatory risks: Changes in regulations related to veterinary diagnostics or healthcare equipment could pose compliance challenges for IDEXX Laboratories.
  • Dependency on key markets: IDEXX Laboratories' revenue is influenced by its performance in key markets like the companion animal veterinary sector, making it susceptible to market fluctuations.
  • Technological advancements: Rapid technological changes in the healthcare sector may require continuous innovation from IDEXX Laboratories to maintain its competitive edge, leading to increased R&D expenses.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price target for 2024?

9 brokerages have issued 12 month target prices for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $655.00. On average, they expect the company's share price to reach $591.50 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2024?

IDEXX Laboratories' stock was trading at $555.05 on January 1st, 2024. Since then, IDXX stock has decreased by 10.3% and is now trading at $497.79.
View the best growth stocks for 2024 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IDXX earnings forecast
.

How can I listen to IDEXX Laboratories' earnings call?

IDEXX Laboratories will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings results on Monday, February, 5th. The company reported $2.32 EPS for the quarter, topping analysts' consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analysts' expectations of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a trailing twelve-month return on equity of 71.66%. The company's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 earnings per share.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share (EPS) guidance of 10.840-11.330 for the period, compared to the consensus EPS estimate of 11.000. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Westwind Capital (0.05%), Bourne Lent Asset Management Inc. (0.05%), Woodstock Corp (0.03%), Bath Savings Trust Co (0.03%), Czech National Bank (0.02%) and Gateway Investment Advisers LLC (0.01%). Insiders that own company stock include Brian P Mckeon, Daniel M Junius, George Fennell, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners